Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis
- PMID: 33882145
- DOI: 10.1002/cncr.33584
Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis
Abstract
Background: More than 3.6 million men in the United States harbor a diagnosis of prostate cancer (PCa). The authors sought to provide in-depth analyses of the causes of death for contemporary survivors.
Methods: The authors performed a population-based cohort study in the United States (2000-2016) to assess causes of death for men diagnosed with PCa stratified by demographics and tumor stage. Using general population data, they calculated standardized mortality ratios (SMRs) as observed-to-expected death ratios.
Results: In total, 752,092 men with PCa, including 200,302 who died (27%), were assessed. A total of 29,048 men with local/regional disease (17%) died of PCa, whereas more than 4-fold men died of other causes (n = 143,719 [83%]). SMRs for death from noncancer causes (0.77; 95% confidence interval [CI], 0.77-0.78) suggested that these men were less likely than the general population to die of most other causes. The most common noncancer cause of death was cardiac-related (23%; SMR, 0.76; 95% CI, 0.75-0.77). Among men with distant PCa, 90% of deaths occurred within 5 years of diagnosis. Although deaths due to PCa composed the majority of deaths (74%), SMRs suggested that men with distant PCa were at heightened risk for death from most other noncancer causes (1.50; 95% CI, 1.46-1.54) and, in particular, for cardiac-related death (SMR, 1.48; 95% CI, 1.41-1.54) and suicide (SMR, 2.32; 95% CI, 1.78-2.96). Further analyses demonstrated that causes of death varied by patient demographics.
Conclusions: Causes of death during PCa survivorship vary by patient and tumor characteristics. These data provide valuable information regarding health care prioritization during PCa survivorship.
Lay summary: Men with early-stage prostate cancer are 4-fold more likely to die of other causes, whereas those with advanced prostate cancer are at increased risk for several causes not related to prostate cancer in comparison with the general population. These findings can help guide physicians taking care of men with a diagnosis of prostate cancer.
Keywords: Surveillance, Epidemiology, and End Results (SEER) program; cause of death; epidemiology; prostatic neoplasms.
© 2021 American Cancer Society.
Comment in
-
Prostate cancer survivorship, deaths, and health care management.Cancer. 2021 Aug 15;127(16):2870-2872. doi: 10.1002/cncr.33588. Epub 2021 Apr 21. Cancer. 2021. PMID: 33882148 No abstract available.
Similar articles
-
Cause of Death During Renal Cell Carcinoma Survivorship: A Contemporary, Population-Based Analysis.Front Oncol. 2022 Jun 2;12:864132. doi: 10.3389/fonc.2022.864132. eCollection 2022. Front Oncol. 2022. PMID: 35719910 Free PMC article.
-
Causes of death among cancer patients in the era of cancer survivorship in Korea: Attention to the suicide and cardiovascular mortality.Cancer Med. 2020 Mar;9(5):1741-1752. doi: 10.1002/cam4.2813. Epub 2020 Jan 20. Cancer Med. 2020. PMID: 31960609 Free PMC article.
-
Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.JAMA Netw Open. 2021 Aug 2;4(8):e2119568. doi: 10.1001/jamanetworkopen.2021.19568. JAMA Netw Open. 2021. PMID: 34351403 Free PMC article.
-
Late mortality among 5-year survivors of childhood cancer: A systematic review and meta-analysis.Cancer. 2024 May 15;130(10):1844-1857. doi: 10.1002/cncr.35213. Epub 2024 Jan 25. Cancer. 2024. PMID: 38271115
-
Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.BJU Int. 2023 Apr;131(4):486-493. doi: 10.1111/bju.15891. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36088648 Review.
Cited by
-
Quantifying Suicide Risk in Prostate Cancer: A SEER-Based Predictive Model.J Epidemiol Glob Health. 2025 Mar 20;15(1):46. doi: 10.1007/s44197-025-00384-z. J Epidemiol Glob Health. 2025. PMID: 40111711 Free PMC article.
-
Cause of Death During Renal Cell Carcinoma Survivorship: A Contemporary, Population-Based Analysis.Front Oncol. 2022 Jun 2;12:864132. doi: 10.3389/fonc.2022.864132. eCollection 2022. Front Oncol. 2022. PMID: 35719910 Free PMC article.
-
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2024 Sep;27(3):393-403. doi: 10.1038/s41391-024-00792-5. Epub 2024 Jan 24. Prostate Cancer Prostatic Dis. 2024. PMID: 38267540
-
Association of N-terminal pro-brain natriuretic peptide with survival among US cancer survivors.J Natl Cancer Inst. 2024 Jun 7;116(6):938-947. doi: 10.1093/jnci/djae008. J Natl Cancer Inst. 2024. PMID: 38299668 Free PMC article.
-
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.JACC CardioOncol. 2024 Sep 3;6(5):761-771. doi: 10.1016/j.jaccao.2024.07.011. eCollection 2024 Oct. JACC CardioOncol. 2024. PMID: 39479325 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.doi:10.3322/caac.21590
-
- Welch HG, Albertsen PC. Reconsidering prostate cancer mortality-the future of PSA screening. N Engl J Med. 2020;382:1557-1563.doi:10.1056/NEJMms1914228
-
- Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med. 2019;381:1378-1386.doi:10.1056/NEJMsr1905447
-
- Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: a population-based retrospective cohort study. Urol Oncol. 2018;36:309.e15-309.e23.doi:10.1016/j.urolonc.2018.02.016
-
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363-385.doi:10.3322/caac.21565
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical